A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
Running, not enrolling
Conditions studied: Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, Hemi-retinal Vein Occlusion
In brief
The VOYAGER study is a primary data collection, non-interventional, prospective, multinational, multicenter study. It is designed to collect real-world, long-term data to explore long-term effectiveness, safety, clinical insights, treatment patterns, and factors driving the treatment decisions among patients being treated with specified Roche ophthalmology products in approved retinal indications (Faricimab for neovascular age-related macular degeneration \[nAMD\], diabetic macular edema \[DME\], and retinal vein occlusion; Port Delivery System with Ranibizumab for nAMD) in routine clinical practice. This study will not provide or make recommendations on use of any products including Roche products; treatment decisions will be determined by the treating physician and must be made independently to the decision to participate in this study. Participation in this study will not change or influence a patient's standard of care in any way.
Key facts
- Study ID
- NCT05476926
- Run by
- Hoffmann-La Roche
- People needed
- 6000
- Starts
- 2022-11-21
- Expected to finish
- 2027-11-30
- Last updated by the study team
- 2026-06-09
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Have provided informed consent, as required per local regulations 2.a) Adult patient, as defined by local regulations and local product label, who is newly initiating treatment (or initiated treatment in the previous visit) with a specified approved Roche ophthalmology product in retinal indication of interest for this study in at least one eye, according to the investigator's discretion in routine clinical practice; OR 2.b) Adult patient, as defined by local regulations and local product label, who is continuing treatment with any specified approved Roche ophthalmology product in retinal indication of interest for this study in at least one eye after initiating that treatment in a Roche interventional trial.
You may not qualify if…
- Concomitant participation of the patient in an investigational ophthalmology clinical trial that includes receipt of any investigational drug or procedure within the last 28 days prior to enrollment (this restriction does not apply to patients who are rolling over from Roche interventional studies and continuing treatment with any specified approved Roche ophthalmology product in retinal indication of interest for this study)
Where it is running
- California Eye Specialists Medical group Inc. — Pasadena, California, United States
- Retinal Consultants Medical Group — Sacramento, California, United States
- Advanced Research — Coral Springs, Florida, United States
- Retina Specialty Institute — Pensacola, Florida, United States
- University Retina and Macula Associates, PC — Lemont, Illinois, United States
- Springfield Clinic, Llp — Springfield, Illinois, United States
- Retina Associates of Kentucky — Lexington, Kentucky, United States
- Cumberland Valley Retina Consultants PC — Hagerstown, Maryland, United States
- Associated Retinal Consultants PC — Royal Oak, Michigan, United States
- Erie Retinal Surgery — Erie, Pennsylvania, United States
- Tennessee Retina PC — Nashville, Tennessee, United States
- Brown Retina Institute — San Antonio, Texas, United States
- Retina Center of Texas — Southlake, Texas, United States
- University of Utah, John Moran Eye Center — Salt Lake City, Utah, United States
- Piedmont Eye Center — Lynchburg, Virginia, United States
- Wagner Macula and Retina Center — Norfolk, Virginia, United States
- Spokane Eye Clinical Research — Spokane, Washington, United States
- Salud Ocular — Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
- Instituto Oftalmologico de Buenos Aires S.A. — Buenos Aires, Argentina
- Centro Oftalmologico Dr. Charles S.A. — Ciudad Autonoma Buenos Aires, Argentina
- Centro Privado de Ojos Romagosa S.A — Córdoba, Argentina
- CEO Centro de Especialidades Oftalmologicas Tucuman — San Miguel de Tucumán, Argentina
- Retina and Macula Specialists — Hurstville, New South Wales, Australia
- Sydney West Retina — Westmead, New South Wales, Australia
- Retinal Research Institute, LLC — Phoenix, Arizona, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.